2022 ECHEMI×API Virtual Business Matching

API China focuses on improving the overall level of production and research and development of pharmaceutical raw materials, intermediates, and pharmaceutical excipients in China, representing new products and technologies in China's pharmaceutical industry. China's API market will already burst with new developments with the implementation of the joint review and approval system. The vitality of Shandong Xinhua Pharmaceutical Co., Ltd., Shanghai Huyuan Pharmaceutical Co., Ltd., Dijia Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Group Co., Ltd., Tianjin Pharmaceutical Group Co., Ltd., China Pharmaceutical and Health Industry Co., Ltd., Jiangxi Fuxiang Pharmaceutical Co., Ltd., Livzon Pharmaceutical Group Co., Ltd., Shanghai Acrono Pharmaceutical Group Co., Ltd., CSPC Holding Group Co., Ltd., Ningxia Taiyixin Biotechnology Co., Ltd., China National Pharmaceutical Group Corporation, Northeast Pharmaceutical Group Co., Ltd. , North China Pharmaceutical Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Puluo Pharmaceutical Co., Ltd., Anhui Puli Pharmaceutical Co., Ltd., Guobang Pharmaceutical Group Co., Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Jiuzhou The "traditional giants" of China's pharmaceutical industry represented by Pharmaceutical Co., Ltd. will gather in Hangzhou with their traditional advantageous products and newly developed new varieties, together with more than 1,000 outstanding Chinese API companies.

www.echemi.com is the official business partner of API China. The past Echemi Sourcing Meeting were all tremendous success. The event will gather up to 20 buyers from the world to have face-to face meeting with more than 1000 exhibitors. We are devoted to help the buyers and suppliers to make the deal easier.